Figure 3 | Scientific Reports

Figure 3

From: Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins

Figure 3

Direct ELISA immunoassays with anti-SARS-CoV-2 antibodies detecting viral spike proteins. The ability and potency of engineered anti-SARS-CoV-2 antibodies to bind to the viral spike proteins was compared using Enzyme-linked immunosorbent assays (ELISAs). SARS-CoV-2 spike protein as either S1 (A,C) or RBD (B,D) was adsorbed onto immunoassay plates at 2 µg per µL for 16 h at 4 C. Wells were thoroughly washed, blocked, and various concentrations of the indicated His-tagged antibodies were added to each well and incubated for 16 h at 4 C, followed by washing and incubation with anti-His-HRP antibody for 2 h at room temperature. Colour was developed using TMB and absorbance read at 450λ. All samples were run in triplicate.

Back to article page